The influence of high-efficiency particulate air filtration on mortally and fungal infection among highly immunosuppressed patients: A systematic review

Journal of Infectious Diseases

Volumn 193, Issue 10, 2006, Pages 1408-1418

  Eckmanns, Tim ^a   Rüden, Henning ^a   Gastmeier, Petra ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; AGRANULOCYTOSIS; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HIGH EFFICIENCY PARTICULATE AIR FILTRATION; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; LYMPHOSARCOMA; MEDLINE; MEMBRANE FILTER; META ANALYSIS; MORTALITY; MYCOSIS; NEUTROPENIA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ROOM VENTILATION; SYSTEMATIC REVIEW;

AIR MICROBIOLOGY; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CROSS INFECTION; FUNGEMIA; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION CONTROL; OPPORTUNISTIC INFECTIONS; PATIENT ISOLATION; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; VENTILATION;

EID: 33646354627     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/503435     Document Type: Review

References (62)

1. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol 1991; 9:77-84.
2. Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96:497-503.
3. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23:608-15.
4. Alberti C, Bouakline A, Ribaud P, et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect 2001; 48:198-206.
5. Rhame FS. Prevention of nosocomial aspergillosis. J Hosp Infect 1991; 18(Suppl A):466-72.
6. Krüger WH, Hornung RJ, Hertenstein B, et al. Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European group for blood and marrow transplantation. J Hematother Stem Cell Res 2001; 10:895-903.
7. Schweigkofler H, Sperner-Unterweger B, Kopp M, Trojer-Zeidler M, Holzner B. Psychiatric problems in bone marrow transplantation patients during isolation [in German]. Nervenarzt 1996; 67:799-804.
8. Sasaki T, Akaho R, Sakamaki H, et al. Mental disturbances during isolation in bone marrow transplant patients with leukemia. Bone Marrow Transplant 2000; 25:315-8.
9. Centers for Disease Control and Prevention. Guidelines for prevention of nosocomial pneumonia. MMWR Recomm Rep 1997;46(RR-1):1-79.
10. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49(RR-10):1-125, CE1-7.
11. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53(RR-3):1-36.
12. Sehulster L, Chinn RY, Centers for Disease Control and Prevention, Healthcare Infection Control Practices Advisory Committee. Guideline for environmental infection control in health-care facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003; 52(RR-10):1-42.
13. Hayes-Lattin B, Leis JF, Maziarz RT. Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transplant 2005; 36:373-81.
14. Rhame FS. The inanimate environment. In: Bennett JV, Brachman PS, eds. Hospital infections. 3rd ed. Boston: Little, Brown, 1992:299-331.
15. Pannuti S. Hospital environment for high risk patients. In: Wenzel RP, ed. Prevention and control of nosocomial infections. 3rd ed. Baltimore: Williams & Wilkins, 1997:463-89.
16. Perl TM, Chotani R, Agawala R. Infection control and prevention in bone marrow transplant patients. In: Mayhall CG, ed. Hospital epidemiology and infection control. 2nd ed. Philadelphia: Williams & Wilkins, 1999:803-44.
17. Lau J, Ioannidis PA, Schmid CH. Quantitative synthesis in systematic reviews. In: Mulrow C, Cook D, eds. Systematic reviews: synthesis of best evidence for health care decisions. Philadelphia: American College of Physicians, 1998:91-101.
18. Egger M, Davey Smith G, O'Rourke K. Rationale, potentials, and promise of systematic reviews. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in healthcare: meta-analysis in context. London: BMJ Books, 2001:3-19.
19. Stata: statistics/data analysis. 7.0 ed. College Station, TX: StataCorp, 2001.
20. Bodey GP, Gehan EA, Freireich EJ, Frei E III. Protected environment-prophylactic a ntibiotic program in the chemotherapy of acute leukemia. Am J Med Sci 1971;262:138-51.
21. Schimpff SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia: laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351-8.
22. Freireich EJ, Bodey GP, Rodriguez V, et al. A controlled clinical trial to evaluate a protected environment and prophylactic antibiotic program in the treatment of adult acute leukemia. Trans Assoc Am Physicians 1975; 88:109-19.
23. Rodriguez V, Bodey GP, Freireich EJ, et al. Randomized trial of protected environment-prophylactic antibiotics in 145 adults with acute leukemia. Medicine (Baltimore) 1978; 57:253-66.
24. Buckner CD, Clift RA, Sanders JE, et al. Protective environment for marrow transplant recipients: a prospective study. Ann Intern Med 1978; 89:893-901.
25. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment, N Engl J Med 1983; 308:302-7.
26. Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 1973; 32:1490-8.
27. Levine AS, Siegel SE, Schreiber AD, et al. Protected environments and prophylactic antibiotics: a prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 1973; 288:477-83.
28. Petersen F, Thornquist M, Buckner C, et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection 1988; 16:199-208.
29. Petersen FB, Buckner CD, Clift RA, et al. Infectious complications in patients undergoing marrow transplantation: a prospective randomized study of the additional effect of decontamination and laminar air flow isolation among patients receiving prophylactic systemic antibiotics. Scand J Infect Dis 1987; 19:559-67.
30. Schmeiser T, Kurrle E, Arnold R, Krieger D, Heit W, Heimpel H. Antimicrobial prophylaxis in neutropenic patients after bone marrow transplantation. Infection 1988; 16:19-24.
31. Gamillscheg A, Urban C, Slavc I, Lackner H, Hauer C. Infections in the neutropenic phase following bone marrow transplantation: comparison of laminar airflow isolation with conventional isolation [in German]. Wien Klin Wochenschr 1991;103:82-7.
32. Lohner D, Debusscher L, Prevost JM, Klastersky J. Comparative randomized study of protected environment plus oral antibiotics versus oral antibiotics alone in neutropenic patients. Cancer Treat Rep 1979; 63:363-8.
33. Navari RM, Buckner CD, Clift RA, et al. Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med 1984; 76:564-72.
34. Rhame FS, Streifel AJ, Kersey JH Jr, McGlave PB. Extrinsic risk factors for pneumonia in the patient at high risk of infection. Am J Med 1984; 76:42-52.
35. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air nitration on nosocomial Aspergillus infections: unique risk of bone marrow transplant recipients. Am J Med 1987; 83:709-18.
36. Withington S, Chambers ST, Beard ME, et al. Invasive aspergillosis in severely neutropenic patients over 18 years: impact of intranasal amphotericin B and HEPA filtration. J Hosp Infect 1998; 38:11-8.
37. Oren I, Haddad N, Finkelstein R, Rowe JM, Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66:257-62.
38. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23:795-805.
39. Cornet M, Levy V, Fleury L, et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 1999; 20:508-13.
40. Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 1990; 336:850-4.
41. Passweg JR, Rowlings PA, Atkinson KA, et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998; 21:1231-8.
42. Meyers JD, Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17:10-3.
43. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.
44. Opal SM, Asp AA, Cannady PB Jr, Morse PL, Burton LJ, Hammer PG II. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 1986; 153:634-7.
45. Murray B, Streifel AJ, O'Dea TJ, Rhame FS, Ventilation for protection of immune compromised patients. ASHARE (American Society of Heating, Refrigerating, and Air Conditioning Engineers) Transactions 1988; 94:1185-91.
46. Streifel AJ, Vesley D, Rhame FS, Murray B. Control of airborne fungal spores in a university hospital. Environment International 1989; 12:441-4.
47. Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. J Hosp Infect 1989; 14:89-94.
48. McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993; 17:397-404.
49. Rogers TR. Infections in hematologic malignancy. Infect Control 1986; 7:140-3.
50. Thio CL, Smith D, Merz WG, et al. Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit. Infect Control Hosp Epidemiol 2000; 21:18-23.
51. Rice N, Streifel A, Vesley D. An evaluation of hospital special-ventilation-room pressures. Infect Control Hosp Epidemiol 2001; 22:19-23.
52. American Institute of Architects. Guidelines for design and construction of hospital and health care facilities, 2001, Washington, DC: American Institute of Architects Press, 2001.
53. Siegler L, Kennedy MJ, Aspergillus, Fusarium, and other opprtunistic moniliaceous fungi. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 7th ed. Washington, DC: American Society for Microbiology Press, 1999:1212-41.
54. Arnow PM, Sadigh M, Costas C, Weil D, Chudy R. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis 1991; 164:998-1002.
55. Breton P, Germaud P, Leroyer C, Madelaine J, Bland J, Clavier J. Unusual pulmonary mycoses in patients with hematologic disease. Rev Pneumol Clin 1998; 54:253-7.
56. Guarro J, Nucci M, Akiti T, Gene J, Barreiro MD, Goncalves RT. Fungemia due to Fusarium sacchari in an immunosuppressed patient. J Clin Microbiol 2000; 38:419-21.
57. Burton JR, Zachery JB, Bessin R. Aspergillosis in four renal transplant patients: diagnosis and effective treatment with amphotericin B. Ann Intern Med 1972; 77:383-8.
58. Kyriakides GK, Zinnemann HH, Hall WH. Immunologic monitoring and aspergillosis in renal transplant patients. Am J Surg 1972; 131:246-52.
59. Rhame FS. Endemic nosocomial filamentous fungal disease: a proposed structure for conceptualizing and studying the environmental hazard. Infect Control 1986; 7:124-5.
60. Weems JJ Jr, Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infect Control 1987;8:71-5.
61. Overberger PA, Wadowsky RM, Schaper MM. Evaluation of airborne particulates and fungi during hospital renovation. Am Ind Hyg Assoc J 1995; 56:706-12.
62. Armstrong D. Symposium on infectious complications of neoplastic disease (part II): protected environments are discomforting and expensive and do not offer meaningful protection. Am J Med 1984; 76:685-9.